Skip to content Skip to footer
BiosHealth
BiosHealth
    MENU

Venture Debt Capital

Close
Complete the Capital Assessment Form to determine eligibility
In today’s challenging capital-raising environment, Life Science companies—such as those in biotech, medical devices, diagnostics, and digital health—face a variety of hurdles. The industry’s heavy reliance on long development timelines, uncertain regulatory pathways, and the demand for capital-intensive R&D makes traditional equity funding more difficult and less appealing.
Venture capital firms are often selective, preferring later-stage companies with lower risk, while IPO and public market options are narrowing. The result is fierce competition for equity funding, higher demands for de-risking, and, in many cases, significant dilution of ownership when equity funding is secured.

This is where our Venture Debt Capital Program emerges as a powerful alternative.

Challenges Life Science Companies Face in Raising Capital:

Life Science companies often have long lead times between R&D, clinical trials, and commercialization. Raising capital through equity during these stages often leads to heavy dilution.
The regulatory landscape, particularly for novel therapeutics and medical devices, can be complex. Investors may demand more equity in exchange for the increased risk.
In current market conditions, valuations can fluctuate significantly, and companies may raise less capital than anticipated or accept more dilution.
Investors are seeking more evidence of de-risked assets (clinical efficacy data, safety profiles, regulatory approvals) before committing, which adds to the capital needs and raises the bar for securing investment.
Life Science companies often give up significant ownership to secure large equity investments, limiting control over strategic decisions and reducing future profit potential for the founders and early stakeholders.

Why Life Science Companies and Healthcare Companies Should Consider Venture Debt Capital as a Strategic Option

Venture Debt Capital offers a solution tailored for Life Science companies looking to raise capital without sacrificing ownership and control. Given the capital-intensiveness of the Life Science industry, Venture Capital Debt offers financial flexibility, helping companies maintain strategic direction and ownership while achieving growth.

Benefits of Our Venture Debt Capital Program for Life Science and Healthcare Companies

Life Science companies often give away significant ownership in early equity rounds. Venture Capital Debt allows you to secure funding without giving up equity, preserving control over your company and ensuring that when your assets gain value, you fully reap the rewards.
In a time-sensitive industry, particularly for companies working through clinical trials or regulatory approvals, access to capital can’t wait. Venture Capital Debt offers a quicker route to securing capital, compared to long equity fundraising timelines.
As Life Science companies grow, strategic decisions regarding partnerships, clinical trial designs, and market entry strategies become even more critical. Debt financing enables you to retain full ownership, so you maintain control over your business direction.
By using debt to strengthen your financial position, you can improve your valuation in future equity rounds, securing better terms and minimizing dilution when you eventually pursue additional equity.
Venture debt offers interest payment deductions, improving your cash flow and tax position. Additionally, debt often comes at a lower cost of capital than equity financing, making it a financially prudent choice in the long term.
With debt financing, you have structured repayment schedules, allowing you to plan your cash flow and manage financial stability as you navigate through different stages of development.
Whether you need to advance your clinical programs, expand your R&D capabilities, or commercialize a new product, Venture Capital Debt offers flexible financing tailored to your unique business needs without relinquishing equity.

With Bios Health Group’s Venture Debt Capital  Program, Life Science and Healthcare companies can access the capital they need to fuel innovation and growth while protecting their long-term value. Our deep expertise in the Life Science sector and strong connections with the debt markets allow us to craft customized debt solutions that support sustainable success, optimize your financial structure, and reduce the need for additional equity raises.

Our Value Proposition for Life Science and Healthcare Companies

With Bios Health Group’s Venture Debt Capital Program, Life Science and Healthcare companies can access the capital they need to fuel innovation and growth while protecting their long-term value. Our deep expertise in the Life Science sector and strong connections with the debt markets allow us to craft customized debt solutions that support sustainable success, optimize your financial structure, and reduce the need for additional equity raises.

Experience

Decades of expertise in Life Science financing.

Customized Solutions

Tailored debt strategies that match your growth objectives.

Financial Flexibility

Predictable, cost-effective financing that fuels growth.

Contact Us

For Venture Debt Capital Program Consideration

Get started today! Complete the Capital Assessment Form to see if you qualify for our Venture Capital program. We’ll schedule a consultation after reviewing your application.

Company Information
Asset Information
Financial Overview
Key Executive and Decision Maker
Current Needs & Challenges